Biotricity Inc. announced expansion of its Cardiac AI Cloud platform: the company is building a cardiac AI clinical model which distills important information to support clinician in cases that require clinical intervention or review. The company expects to file an FDA clearance for its clinical model by the end of the year. The healthcare AI market is projected to soar to $208.2 billion by 2030 per Grand View Research.

With a projected market value of $96.67 billion by 2030, about 30 million patients are currently enrolled in remote patient monitoring (RPM), creating vast quantities of data for clinicians. That number is anticipated to surge to 70.6 billion by 2025, exponentially increasing the data quantity. Biotricity expects its solutions, fueled by its future Cardiac AI Cloud platform, to empower healthcare professionals in the face of increasing resource shortages and a growing chronically ill population.

Providers will be enabled by the Company's revolutionary technology to manage significantly larger patient volumes while being alerted to critical data. This expands the reach of healthcare services to a broader audience, bridging medical accessibility gaps like never before. Already deployed, Biotricity's AI automation engine has demonstrated its effectiveness in increasing operational efficiency while supporting growth.

This effectiveness of Biotricity's approach can already be seen in the company's continually improving margins. The company plans to continue to expand its automation engine alongside the development of its clinical engine. Biotricity is expanding its proprietary cardiac AI clinical model with key partner technologies, including Google's TensorFlow and Amazon Web Services infrastructure.

By harnessing the power of big data and continuous learning engines, the Company is advancing to new heights. Biotricity's focus is now on expanding data capabilities to develop predictive analytics for early detection, preventing the onset of cardiac conditions, and, if heart disease is developed, mitigating adverse events. Through the analysis of anonymized data set comprised of over 500 billion heartbeats and once FDA cleared, the Company's new AI clinical model is poised to enhance diagnostic accuracy, optimize treatment plans, and significantly improve patient outcomes.

Biotricity anticipates filing for FDA clearance for this AI clinical model later this year.